现实生活中使用MASK空气净化器人群的变应原免疫疗法：贝叶斯混合效应模型的结果
Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.
作者信息
Sousa-Pinto Bernardo, Azevedo Luís Filipe, Sá-Sousa Ana, Vieira Rafael José, Amaral Rita, Klimek Ludger, Czarlewski Wienczyslawa, Anto Josep M, Bedbrook Anna, Kvedariene Violeta, Ventura Maria Teresa, Ansotegui Ignacio J, Bergmann Karl-Christian, Brussino Luisa, Canonica G Walter, Cardona Victoria, Carreiro-Martins Pedro, Casale Thomas, Cecchi Lorenzo, Chivato Tomás, Chu Derek K, Cingi Cemal, Costa Elisio M, Cruz Alvaro A, De Feo Giulia, Devillier Philippe, Fokkens Wytske J, Gaga Mina, Gemicioğlu Bilun, Haahtela Tari, Ivancevich Juan Carlos, Ispayeva Zhanat, Jutel Marek, Kuna Piotr, Kaidashev Igor, Kraxner Helga, Larenas-Linnemann Désirée E, Laune Daniel, Lipworth Brian, Louis Renaud, Makris Michaël, Monti Riccardo, Morais-Almeida Mario, Mösges Ralph, Mullol Joaquim, Odemyr Mikaëla, Okamoto Yoshitaka, Papadopoulos Nikolaos G, Patella Vincenzo, Pham-Thi Nhân, Regateiro Frederico S, Reitsma Sietze, Rouadi Philip W, Samolinski Boleslaw, Sova Milan, Todo-Bom Ana, Taborda-Barata Luis, Tomazic Peter Valentin, Toppila-Salmi Sanna, Sastre Joaquin, Tsiligianni Ioanna, Valiulis Arunas, Wallace Dana, Waserman Susan, Yorgancioglu Arzu, Zidarn Mihaela, Zuberbier Torsten, Fonseca João Almeida, Bousquet Jean, Pfaar Oliver
机构信息
MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
CINTESIS-Center for Health Technology and Services Research, University of Porto, Porto, Portugal.
出版信息
Clin Transl Allergy. 2022 Mar;12(3):e12128. doi: 10.1002/clt2.12128.
BACKGROUND
Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies.
OBJECTIVE
To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT.
METHODS
We assessed the MASK-air data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season.
RESULTS
We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2).
CONCLUSION
In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.
背景
关于变应原免疫疗法（AIT）治疗过敏性鼻炎有效性的证据大多来自随机对照试验，来自真实生活研究的数据很少。
目的
比较使用MASK-air应用程序的三组用户中报告的过敏性鼻炎症状控制情况：接受舌下AIT（SLIT）的用户、接受皮下AIT（SCIT）的用户和未接受AIT的用户。
方法
我们评估了自我报告对草花粉过敏的欧洲用户的MASK-air数据，比较了接受SLIT、SCIT和未接受AIT的患者报告的数据。结果变量包括过敏症状对全球及工作的每日影响（通过视觉模拟量表-VAS测量），以及综合症状-药物评分（CSMS）。我们应用了贝叶斯混合效应模型，按患者、国家和花粉季节进行聚类。
结果
我们共分析了1093例草过敏患者的42756天数据，其中包括接受AIT的用户的18479天数据。与未接受AIT相比，SCIT与相似的VAS水平和CSMS相关。与未接受AIT相比，舌下含片SLIT与较低的VAS全球过敏症状值（平均差异=100分制下7.5分；95%可信区间[95%CrI]=-12.1；-2.8）、较低的VAS工作值（平均差异=5.0；95%CrI=-8.5；-1.5）以及较低的CSMS（平均差异=3.7；95%CrI=-9.3；2.2）相关。与SCIT相比，舌下含片SLIT与较低的VAS全球过敏症状值（平均差异=10.2；95%CrI=-17.2；-2.8）、较低的VAS工作值（平均差异=7.8；95%CrI=-15.1；0.2）以及较低的CSMS（平均差异=9.3；95%CrI=-18.5；0.2）相关。
结论
在草花粉过敏患者中，与未接受AIT和SCIT相比，舌下含片SLIT与较低的报告症状严重程度相关。未来需要按照国际统一标准开展和报告AIT真实世界数据的纵向研究，以更好地了解其“真实世界”有效性。
Zotero 插件